The U.S. Food and Drug Administration (FDA) recently approved leucanemab (Lequembi), via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. This is the second of a novel category of medications approved for AD, that targets the AD specific pathology of amyloid beta plaques. The approval was based on the results of a Phase 3 randomized, controlled clinical trial where researchers evaluated the efficacy of the agent in this double-blind, placebo-controlled, parallel-group, dose-finding study of 856 patients with Alzheimer’s disease. Those patients with mild cognitive impairment or mild dementia stage of disease and confirmed presence of amyloid pathology underwent treatment. They received the approved dose of leucanema; 10 milligram/kilogram every two weeks, and reportedly had statistically significant reduction in brain amyloid plaque from baseline to Week 79, compared to the placebo arm, which had no reduction of amyloid beta plaque. These results support the accelerated approval of leucanemab, due to the observed reduction of amyloid beta plaque, a marker of Alzheimer’s disease. Prescribing information includes a warning for amyloid-related imaging abnormalities (ARIA), which are known to occur with antibodies of this class. The most common side effects of leucanemab were infusion-related reactions, headaches, and ARIA.
>> FDA Press Release
NEI Podcast Episode 173 - The PsychopharmaStahlogy Show: Alzheimer’s Disease and the Amyloid Controversy Released January 18, 2023
Encore Presentation Keys to the Future: An Update on the State of Alzheimer’s Diagnosis, Treatment, and Research CME/CE credit: 0.75 | Expires: July 24, 2024
Stahl's Essential Videos Stahl’s Essential Psychopharmacology, Chapter 12a: Dementia: Diagnosis and Causes CME/CE Credit: 0.75 | Expires: October 21, 2024
Stahl's Essential Videos Stahl’s Essential Psychopharmacology, Chapter 12b: Dementia: Treatment of Memory and Cognition CME/CE Credit: 0.50 | Expires: October 28, 2024
Mental Health News Impact of Neuropsychiatric Symptoms in Alzheimer’s Disease Released March 4, 2022
NEI Podcast Episode 163 - Dementia and Geriatric Mental Health with Dr. Danielle Goldfarb Released November 2, 2022
NEI Membership See more NEI Member benefits